Oncology Institute (TOI) Q4 Loss Per Share Improvement Tests Longstanding Profitability Doubts

Simply Wall St.06:24

Oncology Institute (TOI) closed out FY 2025 with Q4 revenue of US$142.0 million and a basic EPS loss of US$0.07, while trailing twelve month figures show revenue of US$502.7 million and a net loss of ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2619818146?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6032000-choice1-main-header/1585186661957","is_english":true,"pubTime":"2026-03-14 06:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2619818146","market":"sg","top_or_hot":-1,"title":"Oncology Institute (TOI) Q4 Loss Per Share Improvement Tests Longstanding Profitability Doubts","media":"Simply Wall St.","content":"<div>\n<p>Oncology Institute (TOI) closed out FY 2025 with Q4 revenue of US$142.0 million and a basic EPS loss of US$0.07, while trailing twelve month figures show revenue of US$502.7 million and a net loss of ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-toi/oncology-institute/news/oncology-institute-toi-q4-loss-per-share-improvement-tests-l\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Oncology Institute (TOI) Q4 Loss Per Share Improvement Tests Longstanding Profitability Doubts</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOncology Institute (TOI) Q4 Loss Per Share Improvement Tests Longstanding Profitability Doubts\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-14 06:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nasdaq-toi/oncology-institute/news/oncology-institute-toi-q4-loss-per-share-improvement-tests-l><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Oncology Institute (TOI) closed out FY 2025 with Q4 revenue of US$142.0 million and a basic EPS loss of US$0.07, while trailing twelve month figures show revenue of US$502.7 million and a net loss of ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-toi/oncology-institute/news/oncology-institute-toi-q4-loss-per-share-improvement-tests-l\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4185","symbol_name":"保健护理机构","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-toi/oncology-institute/news/oncology-institute-toi-q4-loss-per-share-improvement-tests-l","article_id":"2619818146","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6032000-choice1-main-header/1585186661957"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-toi/oncology-institute/news/oncology-institute-toi-q4-loss-per-share-improvement-tests-l","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2619818146","pubTimestamp":1773440657,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Oncology Institute (TOI) closed out FY 2025 with Q4 revenue of US$142.0 million and a basic EPS loss of US$0.07, while trailing twelve month figures show revenue of US$502.7 million and a net loss of US$60.6 million. The company has seen quarterly revenue move from US$100.3 million in Q4 2024 to US$142.0 million in Q4 2025, with basic EPS losses ranging from US$0.21 in Q1 2025 to US$0.07 in Q4, presenting a picture in which top line scale is increasing while margins remain clearly...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4185":"保健护理机构","TOI":"The Oncology Institute"},"translate_title":"肿瘤研究所(TOI)第四季度每股亏损改善测试了长期以来的盈利疑虑","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TOI":1.5},"content_text":"Oncology Institute (TOI) closed out FY 2025 with Q4 revenue of US$142.0 million and a basic EPS loss of US$0.07, while trailing twelve month figures show revenue of US$502.7 million and a net loss of US$60.6 million. The company has seen quarterly revenue move from US$100.3 million in Q4 2024 to US$142.0 million in Q4 2025, with basic EPS losses ranging from US$0.21 in Q1 2025 to US$0.07 in Q4, presenting a picture in which top line scale is increasing while margins remain clearly negative. See our full analysis for Oncology Institute. With the headline numbers on the table, the next step is to see how this trajectory lines up with the most talked about narratives around TOI, and where the latest results might support or challenge those views. See what the community is saying about Oncology Institute NasdaqCM:TOI Earnings & Revenue History as at Mar 2026 AdvertisementRevenue climbs from US$100.3m to US$141.9m  Quarterly revenue moved from US$100.3 million in Q4 2024 to US$141.9 million in Q4 2025, and the trailing twelve months show US$502.7 million compared with US$393.4 million a year earlier. Consensus narrative points to value based contracts and pharmacy growth as key revenue drivers. The data lines up with that view because the larger top line is coming alongside higher pharmacy dispensing revenue and expanding risk based arrangements, even though net income for the trailing twelve months is still a loss of US$60.6 million against earlier trailing losses of US$53.0 million and US$57.5 million.  Losses ease quarter to quarter but stay heavy  Net loss (excluding extra items) narrowed from US$16.1 million in Q1 2025 to US$7.5 million in Q4 2025, and quarterly basic EPS moved from a loss of US$0.21 to a loss of US$0.07 over the same period. Bulls argue that operating improvements and contract maturation can help margins, and the step down in quarterly losses fits that story. Yet the trailing twelve month loss of US$60.6 million and basic EPS loss of US$0.66 still align with the bullish narrative that profitability is not expected within three years, so the recent quarter softens but does not overturn that long running loss pattern.  On a quarter like this where EPS loss improves but the business is still firmly in the red, many bulls focus on how the model could eventually scale to profit, while others question how long that can take and what it might mean for future dilution, so it is worth seeing how both sides lay out their case in detail. 🐂 Oncology Institute Bull Case Low 0.6x P/S versus a US$7.00 target  TOI trades on a P/S of 0.6x against peer and industry levels of 1.7x and 1.2x, and analysts’ consensus price target of US$7.00 sits well above the current share price of US$2.84. Bears highlight deepening losses over five years, negative shareholders’ equity, and recent dilution, and those concerns are grounded in the trailing twelve month net loss of US$60.6 million and an annual loss deterioration rate of about 42.2%. This helps explain why the market is assigning a lower P/S multiple even though analysts still see enough revenue growth potential to support that US$7.00 target.  Skeptics often point to the combination of a low 0.6x P/S and sizeable losses as a sign that the risk side of the story matters as much as the upside, so if you are weighing that angle it helps to read through the full cautious case as well. 🐻 Oncology Institute Bear Case Next Steps To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Oncology Institute on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves. If this mix of upside and concern feels familiar, take a moment to look through the numbers yourself, weigh the trade offs, and check out 2 key rewards and 4 important warning signs before you decide where you stand. See What Else Is Out There TOI is still carrying a trailing twelve month net loss of US$60.6 million, negative shareholders’ equity, and a long running pattern of sizeable losses. If that level of ongoing loss and balance sheet pressure feels uncomfortable, it is worth checking out 69 resilient stocks with low risk scores to focus on companies with more resilient profiles right now.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2619818146","isCrawlerRequest":true}